Abstracts - faqs.org

Abstracts

Business

Search abstracts:
Abstracts » Business

An essential role for Akt1 in dendritic cell function and tumor immunotherapy

Article Abstract:

Akt1 has regulated dendritic cell (DC) survival in innate (LPS-driven) and adaptive (CD40-driven) immune responses by modulating Bcl-2, but not Bcl-(X.sub.L), levels. Atk1 is found to be a critical regulator of DC lifespan and its manipulation in DCs has improved the clinical efficacy of DC-based tumor vaccines, thereby enhancing tumor-specific T-cell responses and eradication of pre-established solid tumors in mice.

Author: Slawin, Kevin M., Spencer, David M., Park, Dongsu, Lapteva, Natalia, Seethammagari, Mamatha
Publisher: Nature Publishing Co.
Publication Name: Nature Biotechnology
Subject: Business
ISSN: 1087-0156
Year: 2006
T cells, Immune response

User Contributions:

Comment about this article or add new information about this topic:

CAPTCHA


Silencing of SOCS1 enhances antigen presentation by dendritic cells and antigen-specific anti-tumor immunity

Article Abstract:

The silencing suppressor of cytokine signaling (SOCS1), which enhances antigen presentation by dendritic cells (DCs) and antigen-specific anti-tumor immunity, is studied. The findings of the study indicate that the SOCS1 represents an inhibitory mechanism qualitatively and quantitatively controlling antigen presentation by DCs, thus improving the antigen-specific anti-tumor immunity.

Author: Lei Shen, Evel-Kabler, Kevin, Strube, Randy, Si-Yi Chen
Publisher: Nature Publishing Co.
Publication Name: Nature Biotechnology
Subject: Business
ISSN: 1087-0156
Year: 2004
Cytokines, Antigens

User Contributions:

Comment about this article or add new information about this topic:

CAPTCHA


A new lease on life for dendritic cell vaccines?

Article Abstract:

A new strategy for improving cancer vaccines based on insights into the regulation of dendritic-cell life span is described. A truncated variant of Akt1 in dendritic cells increases the cell's longevity, advances their maturation and increases the efficacy of dendritic-cell vaccination in murine tumor models.

Author: Nestle, Frank O.
Publisher: Nature Publishing Co.
Publication Name: Nature Biotechnology
Subject: Business
ISSN: 1087-0156
Year: 2006
Care and treatment, Cancer patients, Cancer vaccines

User Contributions:

Comment about this article or add new information about this topic:

CAPTCHA


Subjects list: Research, United States, Dendritic cells
Similar abstracts:
  • Abstracts: Lentiviral vectors ready for prime-time. Bioinformatics prediction of HIV coreceptor usage. Continuous high-titer HIV-1 vector production
  • Abstracts: The role of accounting in the enterprise bargaining process of an Australian university. A negotiated order perspective on public sector accounting and financial control
  • Abstracts: Boeing begins assembly of first plane in $4.2 billion order. McCain blasts Air Force over Boeing tanker deal
  • Abstracts: Antibody-targeted cell fusion. Bringing amyloid into focus. Modifying murine von Willebrand factor A1 domain for in vivo assessment of human platelet therapies
  • Abstracts: Capital One banks on Six Sigma for strategy execution and culture transformation. Attributions of service switching: a study of consumers' and providers' perceptions of child-care service delivery
This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.
Some parts © 2025 Advameg, Inc.